Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

401. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial.

Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. 11551576 2001 09 11 2001 09 20 2016 11 24 0140-6736 358 9283 2001 Sep 01 Lancet (London, England) Lancet Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. 702-10 Low-molecular-weight heparins and heparinoids are superior to unfractionated heparin in the prevention and treatment of venous thromboembolism, but their safety and efficacy in acute ischaemic stroke are inadequately (...) defined. This randomised, double-blind, aspirin-controlled trial tested the safety and efficacy of treatment with high-dose tinzaparin (175 anti-Xa IU/kg daily; 487 patients), medium-dose tinzaparin (100 anti-Xa IU/kg daily; 508 patients), or aspirin (300 mg daily; 491 patients) started within 48 h of acute ischaemic stroke and given for up to 10 days. Primary intracerebral haemorrhage was excluded by computed tomography. Outcome was assessed, with treatment allocation concealed, by the modified

Lancet2001

402. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. 11752357 2001 12 25 2002 01 23 2016 08 03 0028-4793 345 25 2001 Dec 20 The New England journal of medicine N. Engl. J. Med. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. 1809-17 Patients with arthritis and vascular disease may receive both low-dose aspirin and other nonsteroidal antiinflammatory drugs. We therefore investigated potential interactions between aspirin and commonly prescribed arthritis (...) therapies We administered the following combinations of drugs for six days: aspirin (81 mg every morning) two hours before ibuprofen (400 mg every morning) and the same medications in the reverse order; aspirin two hours before acetaminophen (1000 mg every morning) and the same medications in the reverse order; aspirin two hours before the cyclooxygenase-2 inhibitor rofecoxib (25 mg every morning) and the same medications in the reverse order; enteric-coated aspirin two hours before ibuprofen (400 mg

NEJM2001

403. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.

Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. 11274623 2001 03 16 2001 04 05 2014 11 20 0028-4793 344 13 2001 Mar 29 The New England journal of medicine N. Engl. J. Med. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. 967-73 Many patients who have had upper gastrointestinal bleeding continue to take (...) low-dose aspirin for cardiovascular prophylaxis or other non-steroidal antiinflammatory drugs (NSAIDs) for musculoskeletal pain. It is uncertain whether infection with Helicobacter pylori is a risk factor for bleeding in such patients. We studied patients with a history of upper gastrointestinal bleeding who were infected with H. pylori and who were taking low-dose aspirin or other NSAIDs. We evaluated whether eradication of the infection or omeprazole treatment was more effective in preventing

NEJM2001

404. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.

A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. 11794192 2001 11 05 2002 01 16 2014 11 20 0028-4793 345 20 2001 Nov 15 The New England journal of medicine N. Engl. J. Med. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. 1444-51 Despite the use of antiplatelet agents, usually aspirin, in patients who have had an ischemic stroke, there is still a substantial rate of recurrence. Therefore, we investigated whether warfarin (...) , which is effective and superior to aspirin in the prevention of cardiogenic embolism, would also prove superior in the prevention of recurrent ischemic stroke in patients with a prior noncardioembolic ischemic stroke. In a multicenter, double-blind, randomized trial, we compared the effect of warfarin (at a dose adjusted to produce an international normalized ratio of 1.4 to 2.8) and that of aspirin (325 mg per day) on the combined primary end point of recurrent ischemic stroke or death from any

NEJM2001

405. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis

Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis Derry S, Loke Y K Authors' objectives To assess the incidence of gastrointestinal haemorrhage associated with long-term aspirin therapy, and to determine the effect of dose reduction and formulation on the incidence of such haemorrhage. Searching Two (...) authors independently searched MEDLINE and EMBASE from 1990 to 1999 using the free text terms: 'aspirin' or 'acetylsalicylic*', or 'salicylic*'. The authors also selected trials from a list of 200 antiplatelet studies identified in a previous systematic review (see Other Publications of Related Interest), and manually checked the reference lists of retrieved studies. No language restrictions were reported. Study selection Study designs of evaluations included in the review Randomised controlled trials

DARE.2000

406. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis

Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost (...) mg/day), and aspirin (ASA; 50 mg/day) combined with modified-release dipyridamole (MRD; 400 mg/day). Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population consisted of a hypothetical cohort of patients who had survived an initial ischaemic stroke. Setting The setting was secondary care. The economic analysis was carried out in the USA. Dates to which data relate The effectiveness data for clopidogrel and ASA-MRD related

NHS Economic Evaluation Database.2000

407. Aspirin 25mg/extended release dipyridamole 200mg

Aspirin 25mg/extended release dipyridamole 200mg Aspirin 25mg/extended release dipyridamole 200mg Aspirin 25mg/extended release dipyridamole 200mg Sangha K Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Sangha K. Aspirin 25mg/extended release dipyridamole 200mg. University HealthSystem Consortium (UHC). Drug Monograph. 2000 Authors' objectives The UHC Drug (...) their relative advantages, and they address issues concerning therapeutic interchange. Each monograph includes comprehensive information from the primary literature and provides recommendations for appropriate use. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Aspirin; Dipyridamole Language Published English Country of organisation United States Address for correspondence University HealthSystem Consortium, 2001 Spring Rd., Suite 700, Oak Brook, IL 60523 USA. Tel: 630-954-1700; Fax

Health Technology Assessment (HTA) Database.2000

408. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coron

Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coron 10665552 2000 02 15 2000 02 15 2015 06 16 0140-6736 355 9201 2000 Jan 29 Lancet (London, England) Lancet Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial (...) . The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. 337-45 Aspirin lowers risks of death and myocardial infarction in patients with acute coronary syndromes. Intravenous glycoprotein IIb/IIIa receptor antagonists further reduce the rates of ischaemic events in these patients, but the efficacy of long-term oral glycoprotein IIb/IIIa receptor blockade has not been established. We tested whether the oral glycoprotein IIb

Lancet2000

409. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial.

Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. 10665553 2000 02 15 2000 02 15 2015 06 16 0140-6736 355 9201 2000 Jan 29 Lancet (London, England) Lancet Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. 346-51 Oral anticoagulants and aspirin are antithrombotic (...) drugs that are commonly used in patients with vascular disease. We investigated whether either of these treatments prevented more effectively than the other bypass complications after infrainguinal bypass surgery. We did a multicentre, randomised, open trial. 2690 patients who had undergone infrainguinal grafting were randomly assigned oral anticoagulants (target international normalised ratio 3.0-4.5, n=1339) or aspirin (80 mg daily, n=1351). We followed up patients for a mean of 21 months

Lancet2000

410. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial.

Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. 10776741 2000 04 27 2000 04 27 2015 06 16 0140-6736 355 9212 2000 Apr 15 Lancet (London, England) Lancet Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. 1295-302 Previous trials of antiplatelet therapy for the prevention of venous thromboembolism have individually been inconclusive, but a meta (...) . Study treatment was 160 mg daily aspirin or placebo, started preoperatively and continued for 35 days. Patients received any other thromboprophylaxis thought necessary. Follow-up was of mortality and of in-hospital morbidity up to day 35. Among the patients with hip fracture, allocation to aspirin produced proportional reductions in pulmonary embolism of 43% (95% CI 18-60; p=0.002) and in symptomatic deep-vein thrombosis of 29% (3-48; p=0.03). Pulmonary embolism or deep-vein thrombosis was confirmed

Lancet2000

411. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial.

Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. 10770301 2000 05 02 2000 05 02 2015 06 16 0140-6736 355 9211 2000 Apr 08 Lancet (London, England) Lancet Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke (...) Trial. 1205-10 Patients with acute ischaemic stroke and atrial fibrillation have an increased risk of early stroke recurrence, and anticoagulant treatment with heparins has been widely advocated, despite missing data on the balance of risk and benefit. Heparin in Acute Embolic Stroke Trial (HAEST) was a multicentre, randomised, double-blind, and double-dummy trial on the effect of low-molecular-weight heparin (LMWH, dalteparin 100 IU/kg subcutaneously twice a day) or aspirin (160 mg every day

Lancet2000

412. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial.

Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. 10875825 2000 08 04 2000 08 04 2014 06 15 0959-8138 321 7252 2000 Jul 01 BMJ (Clinical research ed.) BMJ Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. 13-7 To determine which groups of patients may derive particular benefit or experience harm from the use of low dose aspirin (...) for the primary prevention of coronary heart disease. Randomised controlled trial. 108 group practices in the Medical Research Council's general practice research framework who were taking part in the thrombosis prevention trial. 5499 men aged between 45 and 69 years at entry who were at increased risk of coronary heart disease. Myocardial infarction, coronary death, and stroke. Aspirin reduced coronary events by 20%. This benefit, mainly for non-fatal events, was significantly greater the lower

BMJ2000 Full Text: Link to full Text with Trip Pro

413. Antihistamines versus aspirin for itching in late pregnancy.

Antihistamines versus aspirin for itching in late pregnancy. BACKGROUND: While not common, itching in pregnancy (not due to liver disease) can be distressing. OBJECTIVES: The objective of this review was to assess the effects of treatment for itching in late pregnancy. SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth Group trials register. In addition, the Cochrane Controlled Trials Register (CENTRAL/CCTR) was searched. Date of last search: April 1999. SELECTION CRITERIA (...) : Randomised trials of treatments for itching in women in late pregnancy with normal liver function. DATA COLLECTION AND ANALYSIS: Trial quality was assessed and data were extracted independently by two reviewers. MAIN RESULTS: One study of 38 women was included. This was a small crossover trial, using alternate allocation. The trial compared a histamine, chlorpheniramine, with aspirin. Aspirin was more effective than chlorpheniramine in relieving itching (odds ratio 2. 39, 95% confidence interval 1.25

Cochrane2000

414. Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee.

Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee. OBJECTIVES: To determine whether there is a difference in the relative efficacy of individual non-steroidal anti-inflammatory drugs (NSAIDs) when used in the management of osteoarthritis (OA) of the knee. SEARCH STRATEGY: We searched Medline (1966-1995) and Bids Embase (Jan-Dec, 1980-1995). The searches were limited to publications in the English language, and were last perfomed in November 1996. We used modified (...) Cochrane Collaboration search strategy to identify all randomised controlled trials. The MeSH heading osteoarthritis was combined with the generic names of the 17 non-aspirin NSAIDs licensed in the UK for the management of OA in general practice. The search of Embase used the term "osteoarthritis" if present in the abstract, title or keywords, and was combined with the generic names of the 17 non-aspirin NSAIDs, only if they were mentioned in the title, abstract or keywords. SELECTION CRITERIA: All

Cochrane2000

415. Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip.

Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip. OBJECTIVES: To review all randomized trials of analgesics and anti-inflammatory therapy in osteoarthritis (OA) of the hip. To determine which non-steroidal, anti-inflammatory drug (NSAID) is the most effective, and which NSAID is the most toxic. SEARCH STRATEGY: We searched the Cochrane Musculoskeletal Group's trials register, the Cochrane Controlled Trials Register and Medline up to August 1994

Cochrane2000

416. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.

Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. BACKGROUND: The most widely studied and prescribed antiplatelet agent for the prevention of stroke and other serious vascular events among high vascular risk patients is aspirin. Aspirin inhibits platelet activation by inhibiting platelet cyclooxygenase and thromboxane production, and reduces the odds of a serious vascular event by about (...) a quarter. The thienopyridines (ticlopidine and clopidogrel) inhibit platelet activation by a different mechanism to aspirin (blocking the ADP receptor on platelets), and so may be more effective than aspirin. OBJECTIVES: The objective of this review was to determine the effectiveness and safety of thienopyridine derivatives (ticlopidine and clopidogrel) versus aspirin for the prevention of serious vascular events (stroke, myocardial infarction (MI) or vascular death) in patients at high risk

Cochrane2000

417. Aspirin for vascular dementia.

Aspirin for vascular dementia. BACKGROUND: For patients with a diagnosis of vascular dementia there is evidence that aspirin is widely prescribed - in one study, completed by geriatricians and psychiatrists in the UK, 80% of patients with cognitive impairment (with vascular risk factors) were prescribed aspirin. However, a number of queries remain unanswered: Is there convincing evidence that aspirin benefits patients with vascular dementia? Does aspirin affect cognition or improve prognosis (...) ? In addition, does the risk of cerebral or gastric haemorrhage outweigh any benefit? The aim of this review is to assess the evidence of effectiveness of aspirin in those with a diagnosis of vascular dementia. OBJECTIVES: To assess the evidence of effectiveness of the use of aspirin for vascular dementia. SEARCH STRATEGY: Computerised databases were searched independently by two reviewers. In addition, relevant websites were searched and some journals were handsearched. Specialists in the field were

Cochrane2000

418. Single dose oral aspirin for acute pain.

Single dose oral aspirin for acute pain. BACKGROUND: Aspirin has been known to be an effective analgesic for many years and is commonly used throughout the world for many different pain conditions. It is important for both prescribers and patients to have the best possible information about the efficacy and safety of analgesics, and this need is reflected in patient surveys which show that postoperative pain is often poorly managed. We also need to benchmark relative efficacy and safety (...) of current analgesics so that we can compare them with new analgesics. OBJECTIVES: To quantitatively assess the analgesic efficacy and adverse effects of a single-dose of aspirin in acute pain of moderate to severe intensity. SEARCH STRATEGY: Randomised trials were identified by searching Medline (1966 to March 1998), Embase (1980 to January 1998), the Cochrane Library (Issue 1,1998) and the Oxford Pain Relief Database (1950 to 1994). SELECTION CRITERIA: The inclusion criteria used were: full journal

Cochrane2000

419. Aspirin for vascular dementia.

Aspirin for vascular dementia. BACKGROUND: For patients with a diagnosis of vascular dementia there is evidence that aspirin is widely prescribed - in one study, completed by geriatricians and psychiatrists in the UK, 80% of patients with cognitive impairment (with vascular risk factors) were prescribed aspirin. However, a number of queries remain unanswered: Is there convincing evidence that aspirin benefits patients with vascular dementia? Does aspirin affect cognition or improve prognosis (...) ? In addition, does the risk of cerebral or gastric haemorrhage outweigh any benefit? OBJECTIVES: To assess the evidence of effectiveness of the use of aspirin for vascular dementia. SEARCH STRATEGY: Computerized databases were searched independently by two reviewers. In addition, relevant websites were searched and some journals were handsearched. Specialists in the field were approached for unpublished material and any publications found were searched for additional references. The most recent search

Cochrane2000

420. A metaregression analysis of the dose-response effect of aspirin on stroke

A metaregression analysis of the dose-response effect of aspirin on stroke A metaregression analysis of the dose-response effect of aspirin on stroke A metaregression analysis of the dose-response effect of aspirin on stroke Johnson E S, Lanes S F, Wentworth C E, Satterfield M H, Abede B L, Dicker L W Authors' objectives To assess the effect of aspirin dose on the risk of stroke. Searching The authors searched the MEDLINE electronic database (dates and search terms not stated). The authors also (...) searched reference lists of retrieved articles for additional relevant studies. The search was limited to studies published prior to April 30, 1996. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) which were placebo-controlled and included an aspirin-only treatment arm. Included studies also had to report the occurrence of stroke alone. Follow-up ranged from 24 to 48 months (average 32 months). Specific interventions included in the review Aspirin

DARE.1999